by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News
The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one...
by MM360 Staff | Apr 2, 2021 | Featured News, Myeloma News
A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
by MM360 Staff | Mar 31, 2021 | Featured News, Myeloma News
The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior...
by MM360 Staff | Mar 27, 2021 | Featured News, Myeloma News
The U.S. Food and Drug Administration Approved Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel) (ide-cel), On Friday March 26th. Ide-cel is the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. The treatment was...
by MM360 Staff | Mar 26, 2021 | Featured News, Myeloma News
Here is a roundup of articles and news stories the MYELOMA360 team found interesting this week. Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions Researchers at Sylvester Comprehensive Cancer Center at the...
by MM360 Staff | Mar 25, 2021 | Featured News, Myeloma News
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma,...
